156 related articles for article (PubMed ID: 11768329)
1. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Jun; 4(3):152-67. PubMed ID: 11768329
[TBL] [Abstract][Full Text] [Related]
2. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
6. Novel camptothecin derivatives.
Legarza K; Yang LX
In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
8. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring.
Beretta GL; Petrangolini G; De Cesare M; Pratesi G; Perego P; Tinelli S; Tortoreto M; Zucchetti M; Frapolli R; Bello E; Manzotti C; Fontana G; Bombardelli E; Battaglia A; Samorì C; Zunino F
Cancer Res; 2006 Nov; 66(22):10976-82. PubMed ID: 17108136
[TBL] [Abstract][Full Text] [Related]
9. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity.
Beretta GL; Zunino F
Biochem Pharmacol; 2007 Nov; 74(10):1437-44. PubMed ID: 17540344
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to camptothecins.
Saleem A; Edwards TK; Rasheed Z; Rubin EH
Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
[TBL] [Abstract][Full Text] [Related]
13. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
14. [Camptothecin and derivatives: a new class of antitumor agents].
Torck M; Pinkas M
J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
[TBL] [Abstract][Full Text] [Related]
15. Camptothecins: a review of their chemotherapeutic potential.
Ulukan H; Swaan PW
Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin radiation sensitization: mechanisms, schedules, and timing.
Rich TA; Kirichenko AV
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):114-20. PubMed ID: 9726103
[TBL] [Abstract][Full Text] [Related]
17. 7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.
Vladu B; Woynarowski JM; Manikumar G; Wani MC; Wall ME; Von Hoff DD; Wadkins RM
Mol Pharmacol; 2000 Feb; 57(2):243-51. PubMed ID: 10648633
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and cytotoxic activity of new 9-substituted camptothecins.
Dallavalle S; Rocchetta DG; Musso L; Merlini L; Morini G; Penco S; Tinelli S; Beretta GL; Zunino F
Bioorg Med Chem Lett; 2008 May; 18(9):2781-7. PubMed ID: 18434153
[TBL] [Abstract][Full Text] [Related]
19. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
20. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
